November 11, 2021
1 minute reading
Source / Disclosures
Kinnucan J. Real-world dispensary data for IBD patients using medicinal cannabis. Presented at: ACG Annual Scientific Meeting; October 22-27, 2021; Las Vegas (mixed meeting).
Disclosures: The book did not mention any relevant financial disclosures.
Using real-world data, researchers identified patterns of medically dispensed cannabis use in patients with IBD, according to a poster presented at the ACG’s annual scientific meeting.
“We know that Cannabis use in IBD patients is common and that many people reported improvement in symptoms associated with inflammatory bowel disease, including pain relief,” jamie English KinokanAnd MDFACG, said an assistant professor of medicine at the University of Michigan during a virtual presentation. “However, patterns of cannabis use, including dosage and route of administration, have not been described in the IBD community. We describe the first true data obtained from IBD patients who received cannabis from a single medical dispensary program.”
In a retrospective chart review, Kinnucan and colleagues evaluated data from 592 patients with IBD (47.3% women; median age, 43.3 years) who were discharged from medical cannabis from Columbia Care in New York City from January 2016 to March 2020. Data analyzed included age, gender, date of first dispensary visit, number and duration of dispensary visits, whether prescription pain relievers were dispensed and reduced between visits, type of cannabis used, prescribed daily dose of THC and/or CBD and route of administration.
The results showed an increase in total exposure to cannabis from the first visit to the last visit in all patients, including an increased exposure to THC from 9.2 mg per day to 19.5 mg per day and an increased exposure to CBD from 7.4 mg per day to 9.3 mg per day, along with a significant decrease in Use of pain relievers. vaping The tincture was the most common method of administration reported.
“Daily cannabis doses were lower than previously published randomized trials in IBD patients, although there was an increase in the daily cannabis dose during the study period,” the researchers wrote.
The researchers also noted differences in cannabis use by gender across the group. The women were older, more likely to have a co-diagnosed with cancer and chronic painYou are more likely to have pain reliever use on the first visit, fewer follow-up dispensary visits, lower cannabis use and a greater increase in the dose of cannabis prescribed from the first visit to the last, compared to men, according to the data.
“Comprehensive prospective studies are needed to assess the effect of cannabis type, route, and dose on clinical efficacy, adverse events, mental health, and quality of life,” Kinokan said.